Researchers found that semaglutide reduced inflammation in the brains of genetically modified mice that mimic Alzheimer’s ...

according to a new study in mice. The findings offer insights into how GLP-1 agonist drugs like semaglutide affect appetite suppression and why pleasing and delicious foods can override these ...

With the help of artificial intelligence, the team identified a previously unknown peptide that appeared to safely reduce the appetite and weight of mice and miniature pigs without causing nausea ...

Lexicon showed mice ate less when taking LX9851 and semaglutide than when on either molecule as a single agent. As importantly for Lexicon’s positioning of LX9851 in chronic weight management ...

There’s limited scientific evidence directly linking semaglutide use to vitamin B12 deficiency or recommending routine vitamin B12 supplementation for people taking semaglutide. Semaglutide is ...

The treated obese mice experienced significant weight loss (primarily from fat) along with improved glucose and insulin tolerance compared to the control group. These effects were comparable to those ...

Bio (IBIO) announced data from a non-GLP non-human primate pharmacokinetics study suggesting IBIO-600, the company’s novel lead asset and a ...

Patients who received semaglutide before MBS from 2017 to 2024 were matched 1:1 with patients who did not receive semaglutide before MBS using nearest-neighbor propensity score matching.

CHICAGO — Semaglutide, a glucagon-like peptide (GLP-1) receptor agonist, has shown convincing benefits in yet another population: patients with peripheral arterial disease (PAD). In the STRIDE ...